Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2023 May;23(5):511-512.
doi: 10.1016/S1473-3099(22)00880-5. Epub 2023 Jan 18.

The benefit of vaccination after previous SARS-CoV-2 infection in the omicron era

Viviane S Boaventura  1 , Thiago Cerqueira-Silva  2 , Manoel Barral-Netto  2
Affiliations
Comment

The benefit of vaccination after previous SARS-CoV-2 infection in the omicron era

Viviane S Boaventura et al. Lancet Infect Dis. 2023 May.
No abstract available

PubMed Disclaimer

Conflict of interest statement

VSB and MB-N are employees of Fiocruz, a federal public institution that manufactures the ChAdOx1 (Oxford–AstraZeneca) vaccine in Brazil, through a full technology transfer agreement with AstraZeneca. Fiocruz allocates all its manufactured products to the Ministry of Health in Brazil for public health use. TC-S declares no competing interests.

Comment on

References

    1. COVID-19 Cumulative Infection Collaborators Estimating global, regional, and national daily and cumulative infections with SARS-CoV-2 through Nov 14, 2021: a statistical analysis. Lancet. 2022;399:2351–2380. - PMC - PubMed
    1. Crotty S. Hybrid immunity. Science. 2021;372:1392–1393.
    1. Bobrovitz N, Ware H, Ma X, et al. Protective effectiveness of previous SARS-CoV-2 infection and hybrid immunity against the omicron variant and severe disease: a systematic review and meta-regression. Lancet Infect Dis. 2023 doi: 10.1016/S1473-3099(22)00801-5. published online Jan 18. - DOI - PMC - PubMed
    1. Jacobsen H, Cobos Jiménez V, Sitaras I, et al. Post-vaccination T cell immunity to omicron. Front Immunol. 2022;13 - PMC - PubMed
    1. Cao Y, Song W, Wang L, et al. Characterization of the enhanced infectivity and antibody evasion of Omicron BA.2.75. Cell Host Microbe. 2022;30:1527–1539. - PMC - PubMed